

Cochrane Database of Systematic Reviews - - Cochrane Review

eFlow® vibrating membrane nebulizer for the treatment of cystic fibrosis (Structured abstract)

Code: HTA-32014000310 **Year:** 2012 **Date:** 2012 - updated: 6 MAY 2014

Author: Pichon Riviere A

Study design (if review, criteria of inclusion for studies)

All randomised or quasi-randomised controlled trials comparing all preparations of oral vitamin A used as a supplement compared to either no supplementation (or placebo) at any dose and for any duration, in children or adults with cystic fibrosis (defined by sweat tests or genetic testing) with and without pancreatic insufficiency.

Participants

Children or adults with CF (defined by sweat tests or genetic testing) with and without pancreatic insufficiency.

Interventions

Vitamin A supplementation

Outcome measures

Primary outcomes 1. Vitamin A deficiency disorders (visual impairment and other ocular dysfunction; skin manifestations, e.g. phrynoderma) 2. Growth and nutritional status (e.g. weight, height, body mass index, z score for weight, etc.) 3. Mortality

Main results

No studies of vitamin A or other retinoid supplementation were eligible for inclusion. However, one randomised study of beta (Î²)-carotene supplementation involving 24 people with CF who were receiving pancreatic enzyme substitution was included. The study compared successive Î²-carotene supplementation periods (high dose followed by low dose) compared to placebo. The results for the low-dose supplementation period should be interpreted with caution, due to the lack of a wash-out period after the high-dose supplementation. The included study did not report on two of the review's primary outcomes (vitamin A deficiency disorders and mortality); results for our third primary outcome of growth and nutritional status (reported as z score for height) showed no difference between supplementation and placebo, mean difference (MD) 0.23 (95% confidence interval (CI) 0.09 to 0.43) (low-quality evidence). With regards to secondary outcomes, supplementation with high-dose Î²-carotene for three months led to significantly fewer days of systemic antibiotics required to treat pulmonary exacerbations, compared to controls, MD 15 days (95% CI 27.60 to 2.40); however, this was not maintained in the second three-month section of the study when the level of Î²-carotene supplementation was reduced, MD 8 days (95% CI 18.80 to 2.80) (low-quality evidence). There were no statistically significant effects between groups in lung function (low-quality evidence) and no adverse events were observed (low-quality evidence). Supplementation affected levels of Î²-carotene in plasma, but not vitamin A levels. The study did not report on quality of life or toxicity.

Authors' conclusions

Since no randomised or quasi-randomised controlled studies on retinoid supplementation were identified, no conclusion on the supplementation of vitamin A in people with CF can be drawn. Additionally, due to methodological limitations in the included study, also reflected in the low-quality evidence judged following the specific evidence grading system (GRADE), no clear conclusions on Î²-carotene supplementation can be drawn. Until further data are available, country- or region-specific guidelines regarding these practices should be followed.

http://www.iecs.org.ar/iecs-visor-publicacion.php?cod_publicacion=1291&origen_publicacion=publicacione

See also

Health Technology Assessment Database - Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi A. eFlow® (nebulizador de membrana vibrante) para el tratamiento de la fibrosis quística. [eFlow® vibrating membrane nebulizer for the treatment of cystic fibrosis] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rápida N°255. 2012

Keywords

non pharmacological intervention - diet; Nutrition Disorders; Supplementation; vitamins; Vitamin A; Vitamin A Deficiency; Vitamin deficiencies; Vitamins; pharmacological_intervention;